These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

759 related items for PubMed ID: 15386332

  • 1. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.
    Cancer; 2004 Oct 15; 101(8):1776-85. PubMed ID: 15386332
    [Abstract] [Full Text] [Related]

  • 2. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.
    Ann Thorac Surg; 2004 Oct 15; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW.
    Ann Surg; 2006 Apr 15; 243(4):472-8. PubMed ID: 16552197
    [Abstract] [Full Text] [Related]

  • 4. Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation.
    Arnett ALH, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL.
    J Thorac Oncol; 2017 Jan 15; 12(1):121-128. PubMed ID: 27569732
    [Abstract] [Full Text] [Related]

  • 5. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW, Koong AC, Chang DT.
    Int J Radiat Oncol Biol Phys; 2012 Oct 01; 84(2):471-7. PubMed ID: 22381904
    [Abstract] [Full Text] [Related]

  • 6. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A.
    J Gastrointest Cancer; 2012 Dec 01; 43(4):612-8. PubMed ID: 22777832
    [Abstract] [Full Text] [Related]

  • 7. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
    Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A, Mortelmans L.
    Ann Oncol; 2002 Mar 01; 13(3):361-8. PubMed ID: 11996465
    [Abstract] [Full Text] [Related]

  • 8. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):358-63. PubMed ID: 17532577
    [Abstract] [Full Text] [Related]

  • 9. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y, Kim JH, Kim SB, Yoon DH, Park SI, Kim YH, Kim HR, Jung HY, Lee GH, Ryu JS.
    J Surg Oncol; 2014 Apr 01; 109(5):472-7. PubMed ID: 24301552
    [Abstract] [Full Text] [Related]

  • 10. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.
    Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG.
    J Thorac Oncol; 2006 Jun 01; 1(5):478-86. PubMed ID: 17409902
    [Abstract] [Full Text] [Related]

  • 11. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy.
    Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH.
    BMC Med Imaging; 2017 Jan 05; 17(1):1. PubMed ID: 28056868
    [Abstract] [Full Text] [Related]

  • 12. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun 05; 156(2):171-9. PubMed ID: 22660205
    [Abstract] [Full Text] [Related]

  • 13. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg S, D'Souza WD, Suntharalingam M, Lu W.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1375-82. PubMed ID: 23219566
    [Abstract] [Full Text] [Related]

  • 14. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.
    Ann Surg; 2013 Jul 01; 258(1):66-76. PubMed ID: 23470576
    [Abstract] [Full Text] [Related]

  • 15. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH.
    Eur J Cancer; 2007 Jun 01; 43(9):1385-91. PubMed ID: 17512192
    [Abstract] [Full Text] [Related]

  • 16. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan 01; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
    Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, Lee JY, Lee KH, Kim BT.
    Ann Surg Oncol; 2010 Jan 01; 17(1):115-22. PubMed ID: 19826877
    [Abstract] [Full Text] [Related]

  • 18. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
    Katsoulis IE, Wong WL, Mattheou AK, Damani N, Chambers J, Livingstone JI.
    Int J Surg; 2007 Dec 01; 5(6):399-403. PubMed ID: 17631431
    [Abstract] [Full Text] [Related]

  • 19. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).
    Klaeser B, Nitzsche E, Schuller JC, Köberle D, Widmer L, Balmer-Majno S, Hany T, Cescato-Wenger C, Brauchli P, Zünd M, Pestalozzi BC, Caspar C, Albrecht S, von Moos R, Ruhstaller T.
    Onkologie; 2009 Dec 01; 32(12):724-30. PubMed ID: 20016233
    [Abstract] [Full Text] [Related]

  • 20. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography.
    Kato H, Fukuchi M, Miyazaki T, Nakajima M, Tanaka N, Inose T, Kimura H, Faried A, Saito K, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K, Nonaka T, Shioya M, Ishikawa H, Sakurai H, Nakano T, Kuwano H.
    Anticancer Res; 2007 Dec 01; 27(4C):2627-33. PubMed ID: 17695425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.